On this page
Key takeaways
• Fisetin is more potent as a senolytic than quercetin in cell culture — the 2018 Mayo Clinic screen identified it as the most potent of ten tested flavonoids (1).
• Quercetin has more human clinical trial data — both as a standalone supplement (blood pressure, exercise recovery) and as part of the founding senolytic combination dasatinib + quercetin (3,4,6).
• Both are flavonols, differ by a single hydroxyl group at position 5. This small difference changes senolytic potency, antioxidant profile, and metabolism.
• Bioavailability is poor for both (5,8). Formulation strategies (liposomal, phytosomal) exist for both compounds.
• Combining fisetin and quercetin is common in longevity practice and mechanistically sensible, though no human RCT has tested the combination specifically.
• Quercetin has an established safety and dosing profile (7); fisetin’s long-term safety data are still emerging.
Quick answer
Fisetin and quercetin are close chemical relatives — both flavonols — with overlapping antioxidant, anti-inflammatory, and senolytic pharmacology. Fisetin is the more potent senolytic in preclinical work (1). Quercetin has more human trial data across a broader range of endpoints (blood pressure, exercise recovery, allergic symptoms) and is the senolytic component of the founding Mayo Clinic dasatinib + quercetin combination (3,4). Both have poor oral bioavailability. Combining them is common in longevity practice and mechanistically sensible — they target overlapping but not identical anti-apoptotic pathways — but no human RCT has tested the combination specifically. If you have to choose only one, fisetin has the stronger preclinical senolytic case; quercetin has the broader clinical evidence. If you take both, take them at the same meal with fat. For the full clinical context, see our complete clinician’s guide.
Structural and mechanistic similarities
Fisetin (3,3′,4′,7-tetrahydroxyflavone) and quercetin (3,3′,4′,5,7-pentahydroxyflavone) are almost the same molecule. Both are flavonols. Both carry hydroxyl groups at positions 3, 3′, 4′, and 7. Quercetin has an additional hydroxyl at position 5; fisetin lacks it. That single difference is the reason they behave slightly differently.
Both compounds are antioxidants (scavenging reactive oxygen species via their hydroxyl groups and activating the Nrf2 antioxidant response pathway). Both are anti-inflammatory (suppressing NF-κB signalling). Both interfere with senescent-cell anti-apoptotic pathways (SCAPs). The specific SCAPs they hit overlap but are not identical — quercetin is more active on some pathways, fisetin on others. This overlap explains why they show additive effects in some senescent-cell assays.
Senolytic potency — fisetin’s edge
The 2018 Mayo Clinic flavonoid screen is the load-bearing paper here (1). Yousefzadeh and colleagues screened ten flavonoids for senolytic activity against senescent mouse embryonic fibroblasts. Fisetin was the most potent — producing 50% reduction in senescent-cell viability at concentrations roughly two- to three-fold lower than quercetin required for the same effect. In vivo, oral fisetin reduced senescent-cell markers in aged mice; oral quercetin alone was less effective, and the pharmaceutical dasatinib + quercetin combination was more potent than either alone.
The mechanistic explanation is that fisetin’s lack of the position-5 hydroxyl gives it a more favourable interaction with BCL-xL and PI3K/AKT than quercetin’s more polar structure. This is preclinical evidence and it applies to cell culture; whether the same potency differential holds in humans at achievable plasma concentrations is unknown — both compounds have poor oral bioavailability that may limit tissue delivery to below the senolytic window regardless of intrinsic potency (5,8).
Human clinical evidence — quercetin’s edge
Quercetin has been studied more extensively in human trials than fisetin — mostly at lower flavonoid-antioxidant doses rather than as a senolytic. A meta-analysis of quercetin supplementation trials for blood pressure reported modest but significant systolic BP reductions (6). Trials in exercise recovery, allergic rhinitis, and cardiovascular risk markers have produced mixed to modestly positive results. Quercetin has a well-characterised safety profile at supplement doses up to approximately 1,000 mg per day, with no serious adverse events across multiple trials (7).
As a senolytic, quercetin has been used almost exclusively in combination with dasatinib — the D+Q protocol developed by James Kirkland at Mayo Clinic. The first-in-human D+Q trial in idiopathic pulmonary fibrosis reported functional improvements at three weeks (3). A follow-up trial in diabetic kidney disease reported reduced p16-positive cells in adipose tissue biopsies after a three-day course (4). Fisetin as a standalone senolytic has not yet reported an equivalent human clinical benefit — the AFFIRM trial (NCT03430037) is the closest test and has been unreported since 2018 (9).
Dose and dosing schedule
|
Approach |
Fisetin |
Quercetin |
|
Pulsed senolytic protocol |
20 mg/kg × 2 days, monthly |
1,000 mg/day × 3 days, monthly (as part of D+Q) |
|
Continuous daily supplement |
100–500 mg with fatty meal |
500–1,000 mg with fatty meal |
|
Combined use |
20 mg/kg × 2 days pulsed |
500–1,000 mg on the same days |
|
Bioavailability-enhanced format |
Hydrogel (Krishnakumar 2022) |
Phytosome / EMIQ / lecithin |
Combined use is common in longevity practice. The theoretical rationale is that overlapping but non-identical SCAP targets may produce additive senolytic effects at lower individual doses — the same reason D+Q works better than either component alone. No human RCT has tested the specific fisetin-plus-quercetin combination. See our dedicated pulse dosing article for the fisetin protocol detail.
Bioavailability comparison
Both flavonols have poor oral bioavailability, but the specifics differ. Fisetin achieves a peak plasma concentration of approximately 10 ng/ml after 1,000 mg unformulated dose (5). Quercetin achieves somewhat higher plasma peaks at equivalent doses (roughly 30–100 ng/ml) but still well below the senolytic window in cell culture (8). Both are extensively metabolised to glucuronides and sulphates within hours, with active parent-compound concentrations dropping below detection by 4–6 hours after dosing.
Formulation strategies exist for both. Quercetin has more mature commercial formulations (phytosome, EMIQ, lecithin-based) with several human pharmacokinetic studies documenting 5- to 20-fold Cmax improvements. Fisetin has fewer validated formulations — the Krishnakumar 2022 hydrogel is the only human PK-validated enhanced format (5). See our bioavailability article and liposomal fisetin article for detail.
Safety profiles
Quercetin has a well-characterised safety profile across multiple trials and years of consumer use — doses up to 1,000 mg/day for weeks to months have been tolerated without serious adverse events (7). Very rare reports of headache and GI upset. Concerns about very high-dose chronic quercetin (multiple grams daily) have included theoretical nephrotoxicity in some animal models, though these have not translated to human clinical concern at typical supplement doses.
Fisetin’s safety profile is similar in the short pulsed protocol — well tolerated in the COVID-FIS and other Mayo Clinic trials — but the long-term daily-dosing safety data are less mature. See our side effects and safety article.
The combination case
A common reader question: should I take fisetin, quercetin, or both?
The theoretical case for combination is mechanistically coherent. Fisetin and quercetin target overlapping but non-identical SCAPs. Different senescent-cell types are more vulnerable to different SCAP inhibitors. Combining two flavonols increases the fraction of senescent cells reached by a given pulse. The dasatinib-plus-quercetin architecture proved this principle at the pharmaceutical level; the fisetin-plus-quercetin combination is the natural-flavonoid version of the same idea.
The empirical case is thinner. No human RCT has tested the specific combination. Preclinical mouse work using fisetin plus quercetin has shown some additive effects but has not been extensively characterised. Combined dosing has been used in longevity practice for several years without documented safety concerns.
The practical recommendation, if you want to try both: pulse them together on the same two days per month. Fisetin at the 20 mg/kg pulsed dose, quercetin at 500–1,000 mg. Take with a fatty meal. Give the tissue 28 days off between pulses. This aligns with the founding D+Q architecture and gives both compounds a chance to reach senolytic tissue concentrations in the same window.
What we still don't know
• Whether fisetin + quercetin produces additive human clinical effects. Not tested in any RCT.
• Whether fisetin’s greater cell-culture potency translates to greater clinical benefit at achievable plasma levels. Bioavailability may make the potency difference clinically irrelevant.
• Whether alternative dosing patterns (e.g., quercetin daily plus fisetin pulsed) offer any benefit over pulsed-together dosing. Not studied.
• How the two flavonols interact with the geraldol metabolite that dominates plasma after oral fisetin dosing.
Bottom line
Fisetin and quercetin are close chemical relatives with overlapping but not identical pharmacology. Fisetin has the stronger preclinical senolytic case; quercetin has the broader human clinical evidence base. Both have poor oral bioavailability. Combining them at pulsed doses is a defensible and common practice in longevity supplementation, mechanistically consistent with the founding D+Q senolytic architecture. If you must choose only one, choose fisetin for senolytic emphasis, quercetin for broader flavonoid supplementation. If you take both, pulse them together on the same two days per month with a fatty meal. For the broader context, see our complete clinician’s guide.
Frequently asked questions
Is fisetin more powerful than quercetin?
As a senolytic in cell culture, yes — fisetin was the most potent of ten tested flavonoids in the 2018 Mayo Clinic screen (1). Whether this translates to clinical superiority in humans is not established.
Should I take fisetin, quercetin, or both?
Both is a defensible and common approach. If you must choose one, fisetin has the stronger senolytic case and quercetin has the stronger general flavonoid evidence.
Can I take fisetin and quercetin together?
Yes. Same meal, same fat co-ingestion, same schedule. No known negative interaction. See our how and when to take fisetin article.
Is quercetin cheaper than fisetin?
Generally yes. Quercetin has a longer commercial history and more established supply chains, so per-milligram cost is typically lower.
Which has better safety data?
Quercetin — more human trials, longer commercial history, better-characterised long-term daily-use profile (7). Fisetin’s safety in short pulsed protocols is well established but long-term daily-use data are less mature.
References
1. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
2. Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955-963. https://pubmed.ncbi.nlm.nih.gov/28273655/
3. Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine. 2019;40:554-563. https://pubmed.ncbi.nlm.nih.gov/30616998/
4. Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019;47:446-456. https://pubmed.ncbi.nlm.nih.gov/31542391/
5. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
6. Larson AJ, Symons JD, Jalili T. Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv Nutr. 2012;3(1):39-46. https://pmc.ncbi.nlm.nih.gov/articles/PMC3262612/
7. Andres S, Pevny S, Ziegenhagen R, et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res. 2018;62(1):1700447. https://pubmed.ncbi.nlm.nih.gov/29127724/
8. Kandemir K, Tomas M, McClements DJ, Capanoglu E. Recent advances on the improvement of quercetin bioavailability. Trends Food Sci Technol. 2022;119:192-200. https://www.sciencedirect.com/science/article/pii/S092422442100781X
9. AFFIRM: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women (NCT03430037). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03430037